Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invitae Corp (NY: NVTA )

1.290 +0.010 (+0.78%)
Official Closing Price Updated: 7:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,266,900
Open 1.250
Bid (Size) 1.270 (7)
Ask (Size) 1.320 (26)
Prev. Close 1.280
Today's Range 1.220 - 1.320
52wk Range 1.180 - 9.180
Shares Outstanding 217,339,666
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
A Look Into Invitae's Debt
 
Via Benzinga
Invitae's Return On Capital Employed Insights
 
Via Benzinga

Performance

YTD
-29.89%
-29.89%
1 Month
-37.98%
-37.98%
3 Month
-24.56%
-24.56%
6 Month
-46.47%
-46.47%
1 Year
-83.46%
-83.46%

More News

Read More
Why Invitae Corporation Shares Are Falling Today
Via Benzinga
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Invitae (NVTA) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Is It Too Late to Buy Invitae Stock?
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Earnings Scheduled For February 28, 2023
Via Benzinga
Invitae Stock: Approach With Caution
Via The Motley Fool
Invitae's Debt Overview
Via Benzinga
Down 78% in 1 Year, Is There Any Hope Left for Invitae?
Via The Motley Fool
If You Invested $10,000 in Invitae in 2018, This Is How Much You Would Have Today
Via The Motley Fool
The 7 Best Stocks to Short This Week
Via InvestorPlace
HR Tech Spinout Performica Closes on its Seed Round
Via Newsworthy
Topics Economy
Exposures Economy
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
Via Talk Markets
Invitae Stock: Bull vs. Bear
Via The Motley Fool
Is Invitae in Danger of Running Out of Money?
Via The Motley Fool
InVitae's 'Long, Uncertain Path' Toward Profitability: Analyst Downgrades Biotech
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
3 Growth Stocks That Haven't Been This Cheap in Years
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Core Scientific Shares Are Trading Lower By Around 32%; Here Are 26 Stocks Moving Premarket
Via Benzinga
Which Is the Better Buy: Vertex or Invitae?
Via The Motley Fool
Looking Into Invitae's Recent Short Interest
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.